RET and medullary thyroid gland carcinoma: In 55 RET-mutant MTC patients who had previously progressed through or not tolerated vandetanib and/or cabozantinib, the objective response rate was 69% (95% CI: 55–81), and the 1-year PFS was 82% (95% CI: 69–90).